STUDY SCHEMA

Screen patients scheduled to receive an FDA approved anti-PD-1/-L1 immune checkpoint inhibitor (ICI) for the first time, alone or in combination with co-treatments

Register and **consent** patients prior to the first infusion of ICIs

Baseline (A1): up to two weeks before the patient's first ICI infusion, collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples
- Saliva sample
- Tumor samples (if available)

During Treatment (A2): up to a week before the patient's second ICI infusion (usually 2-3 weeks after A1), collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples
- Saliva sample

6 Month Follow Up (A3): 6 months ± 1 month after the first ICI infusion, collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples

Annual Follow Up (A4+): 1 year ± 3 months after the first ICI infusion, and yearly thereafter until patient death or study end, collect:
- Clinical record and laboratory data
- Patient Reported Outcomes (PROs)
- Peripheral blood samples

At each infusion while the patient is on ICI treatment, collect Cancer Treatment, Toxicity and Response data

4.0 PARTICIPANT ELIGIBILITY

4.1 Inclusion Criteria

Patients **must**:

4.1.1. Be 18 years of age or older

4.1.2. Self-identify as African/African American/Black (AA), or European American/ Caucasian/white (EA)

- Patients may identify a Hispanic/Latino ethnicity in combination with an AA or EA racial identity

4.1.3. Have a current diagnosis of invasive cancer at stage I-IV

- Patients may have a history of previous cancer diagnosis and cancer treatment not involving immunotherapy

4.1.4. Be scheduled to receive anti-PD-1/-L1 ICI-containing therapy according to FDA labels or NCCN guidelines at Category 1 or 2A as **standard of care** treatment **alone or in combination with co-treatments** (including alternative ICIs)

4.1.5. Be able to speak and read English or Spanish

4.1.6. Be able to provide written or remote informed consent

4.2 Exclusion Criteria

Patients **must not**:

4.2.1. Identify as Asian, Pacific Islander, or American Indian/Alaskan Native

4.2.2. Be diagnosed with melanoma (because melanoma is very rare in AAs)

4.2.3. Currently participate or plan to participate in any other cancer treatment trials

4.2.4. Have received prior immunotherapy for cancer, including checkpoint inhibitors, CAR-T therapy, and/or cytokine therapy